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ABSTRACT
Objective: As common prognostication models in intracerebral hemorrhage (ICH) are developed
variably including patients with early (,24 hours) care limitations (ECL), we investigated its
interaction with prognostication in maximally treated patients and sought to provide a new unbi-
ased severity assessment tool.
Methods: This observational cohort study analyzed consecutive ICH patients (n 5 583) from
a prospective registry over 5 years. We characterized the influence of ECL on overall outcome
by propensity score matching and on conventional prognostication using receiver operating char-
acteristic analyses. We established the max-ICH score based on independent predictors of 12-
month functional outcome in maximally treated patients and compared it to existing models.
Results: Prevalence of ECL was 19.2% (n 5 112/583) and all of these patients died. Yet pro-
pensity score matching displayed that 50.7% (n5 35/69) theoretically could have survived, with
18.8% (n 5 13/69) possibly reaching favorable outcome (modified Rankin Scale score 0–3).
Conventional prognostication seemed to be confounded by ECL, documented by a decreased
predictive validity (area under the curve [AUC] 0.67, confidence interval [CI] 0.61–0.73 vs AUC
0.80, CI 0.76–0.83; p , 0.01), overestimating poor outcome (mortality by 44.8%, unfavorable
outcome by 10.1%) in maximally treated patients. In these patients, the novel max-ICH score
(0–10) integrates strength-adjusted predictors, i.e., NIH Stroke Scale score, age, intraventricular
hemorrhage, anticoagulation, and ICH volume (lobar and nonlobar), demonstrating improved pre-
dictive accuracy for functional outcome (12 months: AUC 0.81, CI 0.77–0.85; p , 0.01). The
max-ICH score may more accurately delineate potentials of aggressive care, showing favorable
outcome in 45.4% (n 5 214/471) and a long-term mortality rate of only 30.1% (n 5 142/471).
Conclusions: Care limitations significantly influenced the validity of common prognostication
models resulting in overestimation of poor outcome. The max-ICH score demonstrated increased
predictive validity with minimized confounding by care limitations, making it a useful tool for
severity assessment in ICH patients. Neurology® 2017;89:423–431
GLOSSARY
AUC 5 area under the curve; CI 5 confidence interval; DNR 5 do not resuscitate; ECL 5 early care limitations; GCS 5
Glasgow Coma Scale; ICH 5 intracerebral hemorrhage; IVH 5 intraventricular hemorrhage; MICH 5 modified intracerebral
hemorrhage score; mRS 5 modified Rankin Scale; NIHSS 5 NIH Stroke Scale; OR 5 odds ratio; PPV 5 positive predictive
value; PS 5 propensity score; ROC 5 receiver operating characteristic.
Over decades, case fatality and long-term outcome have remained unchanged in patients with
intracerebral hemorrhage (ICH).1 Initial aggressive treatment may provide benefit, yet overall
ICH still lacks effective therapies to improve outcome.2–4 End-of-life decisions therefore play an
important role in ICHmanagement.5 To ensure best possible care, treating physicians, relatives,
and patients need accurate information regarding the severity of ICH and its predicted
outcome.6
The most important limitation of existing prognostication models—stated by American
Heart Association/American Stroke Association guidelines—relates to care limitations, i.e.,
withholding/withdrawal of medical support, do-not-resuscitate (DNR) orders, and comfort
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care.5,7,8 The developers of the most com-
monly used grading scale—the ICH score—
recently demonstrated that avoidance of early
DNR orders resulted in substantially lower
mortality than predicted.8 In addition, a pro-
spective study questioned the validity of these
models as physicians’ early clinical judgment
correlated more closely with functional out-
come than prognostic scores.9
In routine management, most ICH patients
receive early (,24 hours) care limitations
(ECL) based on a perceived poor prognosis,
potentially leading to a self-fulfilling proph-
ecy.5,10 Hence, chance of recovery will be
denied, perpetuating this dilemma. This high-
lights the need to reduce an unwanted variabil-
ity of informal physician-based prognostication
and the inaccuracy of models variably including
patients with ECL.8,11,12 The benefits of aggres-
sive care may be underappreciated as no model
focuses exclusively on maximally treated pa-
tients.11,12 As a result, the true prognosis of
functional long-term outcome remains
uncertain.5
Therefore, this study sought to characterize
the influence of ECL on (1) outcome using
propensity score matching and (2) validity of
prognostication by analyses of prediction
models in both maximally treated and overall
ICH patients. Based on identified predictors
in maximally treated patients, we aimed to
develop a grading scale—called the max-ICH
score—to provide severity assessment for func-
tional long-term outcome with minimized
confounding by care limitations.
METHODS Patient selection. We extracted pertinent data for
consecutive ICH patients treated at the Department of Neurology
(University Hospital Erlangen, Germany) from our prospective
institutional ICH registry over a 5-year study period (January 2007–
December 2011). We excluded secondary ICH etiologies, i.e.,
arteriovenous malformations, tumor, trauma, or ICH after acute
thrombolysis or with a platelet count ,50,000/mL. Overall, 621
spontaneous ICH patients of central European descent were iden-
tified. Thirty-eight patients were excluded because they refused
consent (n 5 6), were lost to follow-up (n 5 18), or the aggres-
siveness of care could not be precisely evaluated (n 5 14), as
described below. Altogether, 583 remained for final analyses.
Standard protocol approvals, registrations, and patient
consents. The study was approved by the ethics committee and
informed consent was obtained from patients or legal
representatives.
Early care limitations. We defined ECL as care limitations
actually employed during the first 24 hours after admission.
ECL consisted of withholding or withdrawal of potentially life-
sustaining treatment and induction of comfort care measures
with the expectation that the patient would die as a result.10,13
Life-sustaining treatment included mechanical ventilation, car-
diopulmonary resuscitation, use of vasopressors, antibiotics, or
intracranial surgery (i.e., placement of external ventricular drain
or intraparenchymal intracranial pressure probes, hematoma
evacuation). A written DNR order alone was not considered
a care limitation. Any care limitations during the hospital stay as
well as timing, reason, and mode were evaluated retrospectively
by 2 independent physicians. In cases of inconsistencies, a second
consensus analysis was carried out by a third investigator and if no
consensus was reached the patient was excluded.
Data acquisition. Demographics, medical history, neuroradio-
logic data, and in-hospital measures were extracted, as previously
described.14 In-hospital measures on admission included Glasgow
Coma Scale (GCS), NIH Stroke Scale (NIHSS), brainstem
affection represented by absent pupillary light reflex or corneal
reflex in 1 or both eyes (after controlling for factors compromising
reflex status), mechanical ventilation, type of hospital ward, and
length of hospital stay. For a description of neuroradiologic data
acquisition, see the e-Methods at Neurology.org. Mortality and
functional outcome were recorded for 1 year of follow-up,
determined as short-term (3-month) and long-term (12-month)
outcome. Functional outcome was evaluated by modified Rankin
Scale (mRS) and dichotomized as favorable (mRS 0–3) or unfa-
vorable (mRS 4–6), as previously described.15
Prognostic models: ICH score and modified ICH score.
As most ICH scoring systems target short-term outcome, the
literature review identified only 2 models (ICH score and mod-
ified ICH score [MICH]) developed or validated for 12-month
outcome prognostication.7,16–22 The ICH score was calculated
as previously described, summarizing points for GCS (15–135 0,
12–55 1, 4–35 2), ICH volume (,30 cm35 0,$30 cm35 1),
presence of intraventricular hemorrhage (IVH) (no5 0, yes 5 1),
infratentorial origin (no5 0, yes5 1), and patient age (,805 0,
$80 5 1).7 The predicted short-term mortality for each patient
was determined according to the patient’s ICH score using the
corresponding observed mortality rate from the ICH score devel-
opment cohort (ICH score 0, 0%; 1, 13%; 2, 26%; 3, 72%; 4,
97%; 5, 100%).7,8 The predicted mortality for the present cohort
was calculated as the average of the predicted mortality across pa-
tients, as described previously.7,8 Contrary to the original ICH score
cohort, 1 single patient of our study had an ICH score of 6,
therefore lacking a prior observedmortality rate.7 Only for graphical
comparison of short-term mortality rates between cohorts, we
classified this patient into the next lower category (5; 100%). The
MICH was calculated by summarizing points for GCS (15–13 5
0, 12–55 1, 4–35 2), ICH volume (#205 0, 21–505 1,$51
5 2), and presence of IVH or hydrocephalus (no5 0, yes5 1), as
appropriate.17
Statistical analysis. Statistical analyses were performed with
SPSS version 20.0 (SPSS Inc., Chicago, IL) and R version
2.12.1. Statistical tests were 2-sided, significance level was set at
a 5 0.05, multiple comparisons were corrected by Bonferroni
method (type I error). Missing data were handled as complete case
analyses. Kolmogorov-Smirnov test was used to determine data
distribution. Normally distributed data are shown as mean 6
SD, compared using Student t test; non-normally distributed data
as median and interquartile range, compared using the Mann-
Whitney U test. Pearson x2 and Fisher exact tests were applied to
compare frequency distributions of categorized variables. We
utilized explorative analyses to identify factors associated with
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ECL by stepwise forward multivariable logistic regression models.
To reach homogenous measurement levels and to obtain better
comparability of odds ratio (OR) strengths of ECL-associated
factors, metric measures were transformed into the same cate-
gorical variables according to ICH score determination. Further,
we used propensity score (PS) matching to depict the theoretical
outcome of ECL patients if provided maximal treatment. We
compared the prognostic validity of the ICH score between the
entire cohort and maximally treated patients (i.e., non-ECL pa-
tients) using receiver operating characteristic (ROC) curves and
Youden J statistics.23 Areas under the curves (AUC) were analyzed
using the technique of Hanley and McNeil.24 Positive predictive
values (PPV) for mortality and functional outcome were com-
pared using x2 between test computations and considered not
equal if the observed value exceeded the critical value of 3.84. The
max-ICH score was developed, analyzed, and compared to the
ICH score and MICH.7,17 For further statistical details, see the
e-Methods.
RESULTS This cohort included 583 ICH patients
and baseline characteristics were as follows: age 71
years (612), ICH volume 32.9 cm3 (640.3),
GCS 13 (5–15), infratentorial ICH 67 (11.5%),
IVH 305 (52.3%), not significantly differing from
patients (n 5 38) excluded from analysis. The pres-
ent cohort was comparable to study populations
used for ICH score development and long-term
Table 1 Characteristics of early care limitations patients vs maximally treated patients
Intracerebral hemorrhage (n 5 583) Early care limitations (n 5 112) Maximal treatment (n 5 471) p Value
Age, y 75 6 11 70 6 12 ,0.001
Female sex 64 (57.1) 214 (45.4) 0.03a
Medical history
Hypertension 83 (74.1) 385 (81.7) 0.07
Diabetes mellitus 22 (19.6) 127 (27.0) 0.11
Dyslipidemia 22 (19.6) 152 (32.3) 0.01a
Prior ischemic stroke 24 (21.4) 103 (21.9) 0.92
Prior ICH 5 (4.5) 37 (7.9) 0.21
Antiplatelet medication 37 (33.0) 137 (29.1) 0.41
Oral anticoagulation 18 (16.1) 90 (19.1) 0.46
Admission status
Glasgow Coma Scale 4 (3–7) 13 (10–15) ,0.001
NIHSS 29 (24–32) 11 (5–19) ,0.001
Brainstem affection 75 (67.0) 40 (8.5) ,0.001
ICH score 4 (3–4) 1 (0–2) ,0.001
Neuroradiologic data
Location
Lobar 50 (44.6) 199 (42.3) 0.65
Deep 44 (39.3) 223 (47.3) 0.12
Cerebellar 7 (6.3) 28 (5.9) 0.92
Brainstem 11 (9.8) 21 (4.5) 0.03a
ICH volume, cm3 76.3 6 57.1 22.5 6 26.0 ,0.001
Intraventricular hemorrhage 92 (82.1) 213 (45.2) ,0.001
Graeb score 5 (2–8) 0 (0–3) ,0.001
In-hospital measures
ICP monitoring 11 (9.8) 142 (30.1) ,0.001
Hematoma evacuation 2 (1.8) 28 (5.9) 0.07
Admitted to NCU 71 (63.4) 471 (100.0) ,0.001
Admitted to general ward 41 (36.6) 0 (0.0) ,0.001
Length of hospital stay, d 1 (1–2) 12 (7–19) ,0.001
Abbreviations: ICH 5 intracerebral hemorrhage; ICP 5 intracranial pressure; NCU 5 neurocritical care unit; NIHSS 5 NIH
Stroke Scale.
ICP monitoring consisted of external ventricular drains or intraparenchymal probes. Values are mean 6 SD, n (%), or
median (interquartile range; 25th–75th percentile).
aNot significant after Bonferroni correction.
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functional outcome validation regarding ICH
severity, all with median ICH scores of 2 (1–3); for
comparison, see table e-1.7,16
Early care limitations (<24 hours). The prevalence of
ECL was 19.2% (n 5 112/583); after initial diagno-
sis, 83.9% (n 5 94/112) of patients did not receive
further therapy (withholding) and therapy was with-
drawn within the first 24 hours in 16.1% (n 5 18/
112). All patients with identified ECL died after
a median hospital stay of 1 (1–2) days. A total of
156 care limitations were recorded and 71.8% (n 5
112/156) were judged as ECL. Of all patients, only
3.1% (n 5 18/583) received care limitations within
24–72 hours and 4.5% (n 5 26/583) during the
subsequent clinical course. The median length of hos-
pital stay for patients with delayed care limitations (n
5 44/583) was 7 (3–12) days and reasons involved
hematoma enlargement (n5 23), patient’s presumed
will (n 5 11), or clinical deterioration or lack of
improvement (n 5 10). We therefore consider the
investigated cohort of no ECL as maximally treated
patients (n 5 471).
Table 1 compares baseline characteristics between
patients with ECL and maximal treatment, showing
significant associations for measures integrated in the
ICH score. The seldom-assessed measure brainstem
affection (absent brainstem reflexes) was almost 8
times more frequent in ECL patients and showed
the strongest link to ECL upon multivariable model-
ing (OR 12.79, confidence interval [CI] 6.00–27.27,
p , 0.01), followed by GCS (OR 8.81, CI 3.10–
25.06, p, 0.01), age (OR 7.44, CI 3.42–16.20, p,
0.01) and ICH volume (OR 3.98, CI 2.07–7.66, p,
0.01). ECL prevalence and patient characteristics
were similar compared to previous investigations
(table e-2).
To investigate the theoretical benefit of aggressive
care, we conducted a rigorous PS matching to balance
patients with ECL to maximally treated patients. The
successful matching procedure—statistically consis-
tent outcome predictors between ECL and non-
ECL patients (table e-3)—showed that half (50.7%,
n5 35/69) of the maximally treated patients actually
survived and even achieved favorable long-term out-
come in 18.8% (n 5 13/69). Thus, we theoretically
may have refused patients’ chance of survival in at
least 37.7% (n 5 26/69), as in 13% (n 5 9/69) of
matched ECL cases further maximal treatment was
dissented by patient’s will expressed by advance care
directives.
Validity of outcome prediction. We investigated the
influence of ECL on outcome prognostication using
the ICH score and compared predicted with actual
short-term mortality rates: (1) predicted, (2) entire
cohort, (3) maximally treated cohort (figure 1). For
maximally treated patients, the ICH score predicted
a mortality rate of 29% (n 5 135/471), yet the
observed mortality rate was only 21% (n 5 99/471).
This overestimation increased with rising ICH scores;
i.e., predicted mortality rate of 97.3% for patients
with a score $4 compared to observed mortality rate
of only 42.2%. The ICH score was strongly linked to
applied ECL as 3 of 4 parameters were independently
associated and ROC analyses showed a stronger
association for the ICH score with ECL (AUC 0.88,
CI 0.85–0.91, p, 0.01) than with actual short-term
mortality (AUC 0.80, CI 0.76–0.83, p , 0.01).
In figure 2, we present ROC analyses comparing
the prognostic performances of the ICH score in both
cohorts: (1) entire cohort vs (2) maximally treated
patients. The predictive validity for mortality and
functional outcome decreased in maximally treated
patients (short-term mortality: AUC 0.80, CI 0.76–
0.83 vs AUC 0.67, CI 0.61–0.73, long-term func-
tional outcome: AUC 0.79, CI 0.75–0.82 vs AUC
0.72, CI 0.68–0.75, both p, 0.05). Accordingly, we
observed decreased precision (short-term mortality:
PPV 5 67.0% vs PPV 5 37.0%, long-term func-
tional outcome: PPV 5 83.1% vs PPV 5 74.7%,
both p , 0.05) at optimal cutoffs. Application of the
ICH score’s precision calculated for the entire cohort
led to overestimation of poor outcome in maximally
treated patients, resulting in a net difference of 44.8%
for short-term mortality and 10.1% for long-term
unfavorable outcome.
Novel severity assessment: Themax-ICH score.To account
for the observed inaccuracy and to improve severity
assessment, we created a grading scale—the max-
ICH score—containing all measures independently
Figure 1 Comparison of mortality rates
Observed short-term mortality rate in the entire intracerebral hemorrhage (ICH) cohort (n 5
583) and in maximally treated patients (n 5 471) in contrast to predicted short-term mor-
tality rate by the ICH score.
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associated with unfavorable long-term outcome (mRS
4–6) upon multivariable modeling in maximally
treated patients, i.e., ICH volume (OR 1.02, CI 1.01–
1.03, p , 0.01), age (OR 1.08, CI 1.06–1.10, p ,
0.01), NIHSS (OR 1.11, CI 1.08–1.14, p , 0.01),
IVH (OR 1.66, CI 1.03–2.67, p 5 0.04), and
oral anticoagulation (OR 2.08, CI 1.18–3.68, p 5
0.01) (table e-4). Measures such as infratentorial
ICH, GCS, and brainstem affection failed to improve
the model’s statistical strength or did not reach sig-
nificance. Point assignment was based on identified
statistical potency at optimal cutoffs (figure e-1).
Table 2 demonstrates the point assignment for each of
the 6 max-ICH score components with a total score
ranging from 0 to 10. We compared the max-ICH
score with the ICH score and MICH (figure 3A)
—the only scores validated for long-term outcome
assessment—demonstrating superior predictive validity
for both long-term functional outcome (AUC 0.81, CI
0.77–0.85, p , 0.01) and mortality (AUC 0.77, CI
0.72–0.81, p , 0.01). The same holds true for prog-
nostication in the entire cohort (figure e-2). Analyzing
the influence of ECL on the max-ICH score, we found
no confounding of outcome prediction (functional
outcome, entire cohort: AUC 0.85, CI 0.82–0.88 vs
maximal treatment: AUC 0.81, CI 0.77–0.85, p 5
0.11). In figure 3B, we present long-term outcome data
in maximally treated patients, documenting that almost
half (45.4%, n 5 214/471) of the patients reached
favorable functional outcome and only 30.1% (n 5
142/471) died during 12-month follow-up. Figure 3B
also provides outcome stratification according to the
max-ICH score, indicating point estimates for mortal-
ity and favorable functional outcome with corre-
sponding CIs. To investigate prognostication in
patients potentially prone for care limitations, we
Figure 2 Predictive validities of the ICH score for the entire cohort and maximally treated patients
Receiver operating characteristic curves for the association of the ICH score with short-term (A.a) unfavorable functional
outcome and (A.b) mortality as well as long-term (B.a) unfavorable functional outcome and (B.b) mortality for the entire
cohort and in patients with maximal treatment. AUC 5 area under the curve; CI 5 confidence interval; ICH 5 intracerebral
hemorrhage.
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analyzed the 10% (n 5 45/471) of most severely
affected patients according to ICH score (i.e., all pa-
tients with ICH score $ 4, predicted mortality
$97%). Graphical regression analyses within this
specific subgroup—high risk for poor outcome attri-
bution25—documented improved severity stratification
by the max-ICH score allowing identification of pa-
tients achieving favorable functional long-term out-
come (max-ICH score#5, favorable outcome 30% [n
5 7/23]) (figure e-3). In patients with a predicted
mortality rate of 100% (max-ICH score $ 9 or ICH
score$ 5), care might be considered futile. Comparing
the number of patients potentially being affected by
this prediction, we could document a relative risk
reduction of 81.6% (ICH score 3.8%, n 5 21/583 vs
max-ICH score 0.7%, n 5 4/583; p , 0.01) by the
max-ICH score’s prognostication.
DISCUSSION Almost one-fifth of ICH patients
received ECL and analyses demonstrated the poten-
tial of false poor outcome attribution resulting in
a self-fulfilling prophecy. ECL seemed to influence
the predictive validity of current prognostication
tools especially in maximally treated patients,
leading to overestimation of mortality and unfavor-
able functional outcome. We developed a simple
grading scale—the max-ICH score—which allows
severity assessment less biased by care limitations
and that more accurately delineates the potential of
aggressive care in ICH. Among maximally treated
patients, more than 2-thirds survived and almost
every second patient reached favorable functional
outcome.
A recent nationwide survey conducted in the
United States demonstrated that physicians vary sub-
stantially in ICH prognostic estimates and treatment
recommendations, which may lead to profound dif-
ferences in life and death decision-making.12 Theo-
retically, prognostication models provide point
estimates to reduce this unwanted variability.12
Hemphill et al.7,16 developed the ICH score as a sim-
ple grading scale for ICH in 2001 and it has since
been validated for mortality and functional long-term
outcome. The developers of the ICH score recently
reported in a prospective multicenter study on mod-
erately to severely (GCS# 12) affected ICH patients
that the observed short-term mortality was lower
than predicted under full medical support.8 We
confirmed the diverging short-term mortality under
maximal treatment in all ICH patients irrespective
of neurologic status. We further documented relevant
confounding effects introduced by ECL, resulting
in a reduced predictive validity of conventional
grading scales on functional outcome. In maximally
treated patients, the ICH score fulfills the main pur-
pose it was designed for, i.e., stratifying the risk of
short-term mortality, yet our data demonstrated
increased inaccuracy with overestimation of poor out-
come. As suggested by PS-matched analyses, refusal
of aggressive therapy possibly resulted in self-fulfilling
prophecies diminishing chance of potential recov-
ery.8,26 This seems to have influenced prognostic
models25 and such predicted poor outcome runs the
risk to become self-perpetuating, emphasizing the
need for a less biased approach of severity assessment
in ICH.
We developed the max-ICH score to improve risk
stratification and to evaluate the influence of maximal
treatment on functional long-term outcome. The
integrated measures are routinely assessed during
acute ICH management and incorporate initial imag-
ing data to allow for a quick severity assessment on
admission. The max-ICH score ranges from 0 to 10
and chances of survival and favorable functional
Table 2 Determination of the max-ICH score
Component Points
NIHSS
0–6 0
7–13 1
14–20 2
‡21 3
Age, y
£69 0
70–74 1
75–79 2
‡80 3
Intraventricular hemorrhage
No 0
Yes 1
Oral anticoagulation
No 0
Yes 1
Lobar ICH volume, cm3
<30 0
‡30 1
Nonlobar ICH volume, cm3
<10 0
‡10 1
Total max-ICH score 0–10
Abbreviations: ICH 5 intracerebral hemorrhage; NIHSS 5 NIH Stroke Scale.
All components indicate measures on initial examination or initial CT/MRI. Lobar ICH was
defined as ICH originating at the cortex and cortical–subcortical junction.31 Nonlobar ICH
included deep, cerebellar, and brainstem origin. Deep ICH location was defined as ICH
exclusively involving basal ganglia, thalamus, internal capsule, and deep periventricular
white matter.31 ICH encompassing both deep and lobar location should be scored according
to the location that ICH most likely originated from. Thus, more than 1 point referring to ICH
volume can only be reached by the rare event of 2 distinct ICH (1 large lobar and 1 large
nonlobar ICH).
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long-term outcome decrease with rising score values.
Yet point estimates are provided and remain relevant
up to the top end of the score as the important pro-
portion of patients prone to false poor outcome attri-
bution is significantly decreased. In patients with
a score above 7, none reached favorable functional
outcome, while in patients with a score below 2, more
than 9 out of 10 achieved functional independence at
1 year. Although the max-ICH score was predictive of
outcome, exact prognostication for an individual is
not possible.7,8 The aim of the present score is not
to identify patients in whom further care is futile but
to show in which patients aggressive care is warranted
and potentially beneficial. Despite the remaining
uncertainty of cohort-based models, prognostic infor-
mation is needed to support shared decision-making
Figure 3 Prognostication by the max-ICH score in maximally treated ICH patients
(A) Receiver operating characteristic curves for the association of the max-ICH score, the ICH score, and the modified intra-
cerebral hemorrhage score (MICH) with (A.a) unfavorable functional long-term outcome and (A.b) long-term mortality. (B)
Functional long-term outcome evaluated by modified Rankin Scale (mRS) in relation to max-ICH score classification provid-
ing point estimates for mortality and favorable functional outcome (mRS 0–3) with corresponding confidence intervals.
AUC 5 area under the curve; ICH 5 intracerebral hemorrhage.
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early in the setting of ICH8,25 and needs to be as
accurate, unbiased, and invariable as possible.
The present study has several strengths, as out-
come data were prospectively collected until 12-
month follow-up and rigorous statistical tools have
been applied. We consider the present cohort to be
representative and valid for outcome prediction, as
analysis of the ICH score’s predicted short-term mor-
tality with a pooled analysis of 9 cohorts including
3,819 participants worldwide confirmed comparabil-
ity (present study: AUC 0.80, CI 0.76–0.83 vs
pooled analysis: AUC 0.80, CI 0.77–0.8527). More-
over, ECL determination seems to be valid as we
confirmed prevalence and characteristics (i.e., older
age, lower GCS, greater ICH volume) compared to
related studies.10,26,28,29
Shortcomings limit the interpretation of our find-
ings. First, the study was monocentric and specific
center characteristics may not be transferable. Deci-
sions to limit maximal care were based on estimation
by attending physicians in accordance with the pa-
tient’s will or presumed will. Second, although other
measures were collected prospectively, ECL were
scored retrospectively, possibly attenuating data qual-
ity. Third, exclusion of ECL patients could have led
to selection bias, as patients with a theoretic potential
for recovery may have been falsely classified. How-
ever, validity of outcome prediction was based on
ICH scores, which likely provided protection against
bias due to severity adjustments.8 As the max-ICH
score was developed in a selected cohort (i.e., maxi-
mally treated patients), its application to all ICH
patients should be carefully evaluated. Nevertheless,
we provide a model based on predictors identified
in a cohort with minimized confounding due to
care limitations, which led to higher predictive
validity not only in patients chosen for maximal treat-
ment but also in the entire cohort of ICH patients.
We further cannot exclude prehospital transferal ef-
fects. Finally, despite exclusion of ECL patients, out-
come predictors may be affected by delayed care
limitations (7.5%, n5 44/583). However, this small
number of patients received maximal treatment
unsuccessfully and did not influence overall prognos-
tication (data not shown). Furthermore, exclusion of
all patients with care limitations during the hospital
stay seems unreasonable as almost all in-hospital
deaths receive some form of care limitation in neuro-
critical care.30
Despite the inherent limitations of cohort studies,
we provide evidence that commonly used prognosti-
cation models in ICH may be influenced by care lim-
itations, resulting in reduced validity and
overestimation of poor outcome. Theoretically,
ECL may have denied some patients’ chance of recov-
ery, as observed long-term outcome in maximally
treated patients was more favorable than perceived.
We introduced a grading scale developed in maxi-
mally treated patients, allowing for severity assess-
ment with minimized confounding by care
limitations. The max-ICH score may improve multi-
modal assessment of ICH patients, may aid interphy-
sician communication and clinical research
investigations, and may help to evaluate long-term
treatment and recovery goals.8 However, validation
through improved study design seems strongly
warranted.
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